Capricor Therapeutics Inc

CAPR remains in a deep Stage 4 decline with all moving averages sloping downward and price trading below key MAs. Extreme oversold readings suggest a tactical bounce, but the long-term trend stays bearish. Mean-reversion eligibility forces a bullish medium-term bias, permitting only countertrend entries. Short-term execution is deferred until we see support confirmation or an initial relief rally into falling EMAs.

• ↑Share price jumped 97% post-FDA application amendment; Cantor Fitzgerald set $28 target.
• ↑HOPE-3 data showed Deramiocel slowed DMD upper-limb decline by 54%.
• ↓Q2 operating expenses rose 55% YoY to $42.9 M, driving a $40.7 M net loss ($0.70/share).